INTRODUCTION: The utility of blood-based Alzheimer's disease (AD) biomarkers in predicting clinical trajectories remains uncertain. METHODS: We assessed the diagnostic and prognostic performance of p-tau181, p-tau217, GFAP, and NfL in a large memory-clinic cohort (n=3,645) with comprehensive baseline clinical evaluatio...
Xue-Mei Zeng, Nicholas Heaton, Rebecca A. Deek et al.· medRxiv· 0 citations
Background: Alzheimer's disease (AD) is a complex neurodegenerative disorder strongly influenced by genetic factors, with apolipoprotein E (APOE) {epsilon}4 allele being the most established risk variant. Although DNA-based genotyping remains standard, plasma proteotyping may provide scalable, isoform-specific alternat...
Ru-Yu Shi, L. Choity, M. Farinas et al.· medRxiv· 0 citations
It is shown that elevated plasma GFAP significantly modulates the association between p-tau217 and both cross-sectional cognitive severity and longitudinal clinical decline, and support that astrocyte reactivity is associated with greater cognitive impairment and faster clinical decline among individuals with elevated...
B. Bellaver, G. Povala, P. C. L. Ferreira et al.· Molecular Neurodegeneration· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.